达拉非尼联合曲美替尼治疗BRAFV600突变黑色素瘤脑转移患者(COMBI-MB):一项多中心、多队列、开放标签、2期试验
COMBI-MB研究在32家医院纳入125例BRAFV600突变黑色素瘤脑转移患者,分4个队列口服达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次。队列A颅内缓解率58%(95%CI 46-69),B、C、D队列分别为56%、44%、59%。联合方案有活性且安全性可控,但中位缓解持续时间相对较短;作者支持需进一步研究以改善脑转移患者结局。
要点
- 队列A的76例患者中44例(58%;95%CI 46-69)达到颅内缓解。
- 队列B、C、D颅内缓解率分别为56%、44%、59%。
- 常见严重不良事件为发热(达拉非尼相关,8/125)和射血分数下降(曲美替尼相关,5/125)。
核心结论
- 达拉非尼联合曲美替尼在该黑色素瘤人群中具有活性且安全性可控,与既往无脑转移的BRAFV600突变黑色素瘤研究一致,但中位缓解持续时间相对较短。
- 这些结果为达拉非尼联合曲美替尼的临床获益提供证据,并支持需进一步研究以改善黑色素瘤脑转移患者的结局。
研究设计与样本
- 这是一项正在进行的多中心、多队列、开放标签、2期研究,评估口服达拉非尼150 mg每日两次联合口服曲美替尼2 mg每日一次。
- 研究从欧洲、北美和澳大利亚的32家医院和机构纳入125例黑色素瘤脑转移患者,分为4个队列:队列A为BRAFV600E阳性、无症状、无既往局部脑治疗、ECOG评分0或1;队列B为BRAFV600E阳性、无症状、有既往局部脑治疗、ECOG评分0或1;队列C为BRAFV600D/K/R阳性、无症状、有或无既往局部脑治疗、ECOG评分0或1;队列D为BRAFV600D/E/K/R阳性、有症状、有或无既往局部脑治疗、ECOG评分0、1或2。
- 主要终点为队列A全部治疗患者人群中研究者评估的颅内缓解;次要终点包括队列B、C和D的颅内缓解。
- 研究注册号为ClinicalTrials.gov NCT02039947。
主要发现
- 2014年2月28日至2016年8月5日共入组125例患者:队列A 76例,队列B 16例,队列C 16例,队列D 17例。
- 数据截止2016年11月28日,中位随访8.5个月(IQR 5.5-14.0),队列A的76例中44例(58%;95%CI 46-69)达到颅内缓解。
- 研究者评估的颅内缓解在队列B为16例中9例(56%;95%CI 30-80),队列C为16例中7例(44%;20-70),队列D为17例中10例(59%;33-82)。
- 与研究治疗相关的最常见严重不良事件为达拉非尼相关的发热(125例中8例[6%])和曲美替尼相关的射血分数下降(5例[4%])。
- 无论与研究药物关系如何,最常见的3级或更严重不良事件为发热(125例中4例[3%])和头痛(3例[2%])。
关键数值与推荐
- 队列A颅内缓解率58%(95%CI 46-69),队列B为56%(95%CI 30-80),队列C为44%(20-70),队列D为59%(33-82)。
- 达拉非尼给药方案为150 mg每日两次口服,曲美替尼为2 mg每日一次口服。
临床怎么用
- 作者认为,达拉非尼联合曲美替尼在这些黑色素瘤脑转移患者中具有活性且安全性可控,但中位缓解持续时间相对较短。
- 作者支持需进一步研究以改善黑色素瘤脑转移患者的结局。
局限性
- 作者指出中位缓解持续时间相对较短。
- 作者指出这些结果支持需进一步研究以改善黑色素瘤脑转移患者的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dabrafenib plus trametinib improves clinical outcomes in BRAFV600-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases. METHODS: This ongoing, multicentre, multicohort, open-label, phase 2 study evaluated oral dabrafenib (150 mg twice per day) plus oral trametinib (2 mg once per day) in four patient cohorts with melanoma brain metastases enrolled from 32 hospitals and institutions in Europe, North America, and Australia: (A) BRAFV600E-positive, asymptomatic melanoma brain metastases, with no previous local brain therapy, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (B) BRAFV600E-positive, asymptomatic melanoma brain metastases, with previous local brain therapy, and an ECOG performance status of 0 or 1; (C) BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases, with or without previous local brain therapy, and an ECOG performance status of 0 or 1; and (D) BRAFV600D/E/K/R-positive, symptomatic melanoma brain metastases, with or without previous local brain therapy, and an ECOG performance status of 0, 1, or 2. The primary endpoint was investigator-assessed intracranial response in cohort A in the all-treated-patients population. Secondary endpoints included intracranial response in cohorts B, C, and D. This study is registered with ClinicalTrials.gov, number NCT02039947. FINDINGS: Between Feb 28, 2014, and Aug 5, 2016, 125 patients were enrolled in the study: 76 patients in cohort A; 16 patients in cohort B; 16 patients in cohort C; and 17 patients in cohort D. At the data cutoff (Nov 28, 2016) after a median follow-up of 8·5 months (IQR 5·5-14·0), 44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response. Intracranial response by investigator assessment was also achieved in nine (56%; 95% CI 30-80) of 16 patients in cohort B, seven (44%; 20-70) of 16 patients in cohort C, and ten (59%; 33-82) of 17 patients in cohort D. The most common serious adverse events related to study treatment were pyrexia for dabrafenib (eight [6%] of 125 patients) and decreased ejection fraction (five [4%]) for trametinib. The most common grade 3 or worse adverse events, regardless of study drug relationship, were pyrexia (four [3%] of 125) and headache (three [2%]). INTERPRETATION: Dabrafenib plus trametinib was active with a manageable safety profile in this melanoma population that was consistent with previous dabrafenib plus trametinib studies in patients with BRAFV600-mutant melanoma without brain metastases, but the median duration of response was relatively short. These results provide evidence of clinical benefit with dabrafenib plus trametinib and support the need for additional research to further improve outcomes in patients with melanoma brain metastases. FUNDING: Novartis.
引用
- Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017. PMID: 28592387. doi:10.1016/S1470-2045(17)30429-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。